SCHEMBL970568

SCHEMBL970568

CCn1cc(CC(=O)OC)c(C(=O)O)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 1/20 0.35
PDGFRB P09619 1/20 0.34
FGFR1 P11362 1/20 0.34
PDGFRA P16234 1/20 0.34
FLT1 P17948 1/20 0.34
FGFR3 P22607 1/20 0.34
KDR P35968 1/20 0.34
HCAR2 Q8TDS4 1/20 0.34
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33
KDM4E B2RXH2 5/20 0.33
ALDH1A1 P00352 4/20 0.33
HPGD P15428 2/20 0.33
TSHR P16473 2/20 0.33
GLA P06280 2/20 0.33
RAB9A P51151 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GAA P10253 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
EGFR P00533 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL970535 0.80 HSP90AB1 (0.37) HSP90AB1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL969676 0.70 NOTUM (0.39) HCAR2KDM4EALDH1A1HPGDTSHR
SCHEMBL3916488 0.69 FOLH1 (0.50) KDM4EALDH1A1HPGDTSHRHSD17B10
SCHEMBL14565681 0.67 HSP90AB1 (0.44) HSP90AB1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL14354674 0.66 HSP90AB1 (0.56) HSP90AB1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL27560436 0.66 CA1 (0.43) HSP90AB1PDGFRBFGFR1PDGFRAFLT1
SCHEMBL13209936 0.65 CYP2C9 (0.48) KDM4EHPGDTSHRGAAL3MBTL1
SCHEMBL31455720 0.65 MRGPRX4 (0.46) KDM4EHPGDHSD17B10MAPK1
SCHEMBL21464140 0.65 HSD17B10 (0.51) KDM4EALDH1A1HPGDRAB9AHSD17B10
SCHEMBL4608397 0.65 KDM4E (0.49) KDM4EALDH1A1TSHRHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875745-B2 {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4- methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid; for urinary system disease selected from the group of prostatic hypertrophy, neurogenic bladder dysfunction disease, dysuria, pollakiuria, night urination and urodynia ONO PHARMACEUTICAL CO., LTD. (JP) 2011-01-25 US disclosed
US-20070149595-A1 Compounds having lysophosphatidic acid receptor antagonism and uses thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149595-A1 Compounds having lysophosphatidic acid receptor antagonism and uses thereof LPAR2, LPAR1, LPAR5 HSP90AB1 4754/4885PDGFRB 2787/4885FGFR1 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.